Absorption, distribution, metabolism, elimination
Pharmacokinetics asks what the body does to a substance over time: how it is absorbed, moves through tissues, is transformed, and is cleared. The term does not by itself describe benefit or harm.
Ibogaine glossary / mechanism primer
How It Works
Ibogaine is discussed through a mix of pharmacology, metabolism, electrocardiography, and lived experience. This primer gives the terms a plain-language frame: what happens after exposure, why noribogaine is often mentioned, and why the same mechanisms that are studied for possible effects also matter for risk.
For the larger orientation behind the terminology, the Ekoa Strand glossary resource places definitions alongside cautious context rather than promises. A short account of how the resource handles evidence and uncertainty explains the same evidence-first approach.
A working vocabulary
Three layers of the same discussion
Some words describe where a compound goes, some describe what it interacts with, and some describe the heart’s electrical recovery. Keeping those layers distinct makes technical claims easier to read critically.
Receptors, transporters, and signaling
Pharmacodynamics asks what a substance does at biological targets. For ibogaine and noribogaine, discussions often include NMDA-related signaling, kappa opioid receptors, and serotonin transporters.
QT, QTc, hERG, and rhythm risk
Electrophysiology describes the heart’s electrical activity. These terms matter because delayed electrical recovery can be visible on an ECG and, in some circumstances, precede dangerous rhythm disturbances.
From ibogaine to noribogaine
Metabolism changes the timeline
After absorption, ibogaine is metabolized in the body to noribogaine. This is why a glossary often treats the two names separately: a parent compound and its metabolite can have overlapping but not identical pharmacology or timing. The National Library of Medicine’s ibogaine compound record is one reference point for the basic chemical identity behind the term.
The acute psychoactive window is generally described as the earlier period in which perceptual and subjective effects are most prominent. Noribogaine is discussed as having a longer persistence than that acute window, which means a timeline graphic should show two related tracks rather than a single on-and-off event. A documentary context for ibogaine may introduce the subject through experience, while pharmacokinetic language addresses a different question: what is present in the body, and when.
Diagram-ready timing language
- Early phaseAbsorption begins; ibogaine is the named parent compound most often associated with the acute psychoactive window.
- Metabolic phaseEnzymatic metabolism produces noribogaine, a metabolite with its own receptor and transporter activity under study.
- Later phaseNoribogaine may remain relevant after the acute window has passed; duration varies with biology, co-exposures, and other factors.
“Half-life” is a technical measure of decline in concentration, not a guarantee about how long a person will feel an effect. It is useful for describing persistence, but it does not replace the broader safety context addressed in discussions of ibogaine treatment in Mexico or determine whether any setting is appropriate for an individual.
Targets are not outcomes
Receptor systems: a map, not a promise
Ibogaine is commonly characterized as pharmacologically complex rather than selective for one target. Glossary entries may refer to NMDA receptor systems, kappa opioid receptors, and serotonin transporters because these systems are connected to signaling relevant to perception, mood, pain, reward, and stress. The NMDA receptor overview can help distinguish a receptor category from a clinical claim.
“Transporter” has a particular meaning: it is a protein that helps move a chemical messenger across a cell membrane. Serotonin transporter language is therefore different from serotonin receptor language. Likewise, mentioning kappa activity identifies an interaction under study; it does not establish why any reported change occurs, how durable it is, or whether it applies across people. Readers examining claims about reported ibogaine treatment success rates benefit from keeping that distinction in view.
Mechanistic hypotheses can be relevant to research questions, including questions raised around ibogaine and Parkinson’s disease or ibogaine for PTSD treatment. They should not be treated as clinical guidance, a substitute for evidence, or a basis for predicting benefit.
A target is a biological point of contact. It is not a diagnosis, a treatment plan, or evidence that a result will occur.
Why cardiac terms appear so often
QT prolongation and the hERG channel
An electrocardiogram, or ECG, records the heart’s electrical activity. The QT interval represents part of the time from ventricular activation through electrical recovery. Because QT duration changes with heart rate, clinicians often use QTc: the QT interval corrected for heart rate. The FDA’s drug-development guidance resources reflect why drug-related cardiac electrical effects are evaluated as a serious safety concern.
hERG is the commonly used name for a potassium-channel system important to cardiac repolarization, the electrical reset that follows each heartbeat. When a substance blocks this channel, repolarization can be delayed. In plain terms, the electrical recovery phase can lengthen; on an ECG, that may appear as QT prolongation. Ibogaine has been documented as a compound with hERG-blocking activity, which is one reason the glossary cannot separate mechanism language from cardiac risk language.
Torsades de pointes is a distinctive, potentially dangerous ventricular rhythm associated with prolonged QT in susceptible circumstances. The term is not interchangeable with QT prolongation: prolongation is a measurement finding, while torsades de pointes is an arrhythmia. The torsades de pointes reference overview describes the rhythm as a form of polymorphic ventricular tachycardia.
Terms in context
Questions readers often bring to the glossary
Definitions are most useful when they preserve both precision and uncertainty. These short explanations return to the distinction between a biological mechanism, an observed measurement, and a claimed outcome.
What is noribogaine?
Noribogaine is a metabolite formed as ibogaine is processed in the body. It is commonly discussed because it may remain present beyond the acute psychoactive window and has pharmacological activity of its own.
What does QTc mean?
QTc is the QT interval on an ECG after correction for heart rate. It is used as a standardized way to assess a heart-rhythm measurement that can be affected by drugs and other factors. Questions about the cost of ibogaine treatment should never eclipse the importance of understanding this risk vocabulary.
Why is hERG discussed with ibogaine?
hERG refers to a cardiac potassium channel. Blocking this channel can delay electrical repolarization, contribute to QT prolongation, and create conditions associated with torsades de pointes in susceptible situations. The terminology belongs with careful risk interpretation, not reassurance or alarmism.
Keep the terms connected to their limits.
Mechanism language can clarify why ibogaine is studied and why cardiac safety concerns are documented. It cannot determine safety, benefit, legality, or suitability for a particular person.